Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aevi Genomic Medicine, Inc. (CERC)
|
Add to portfolio |
|
|
|
| Price: |
$0.17
| | Metrics |
| OS: |
64.8
|
M
| |
|
|
| Market cap: |
$10.7
|
M
| |
|
|
|
Net cash:
|
$2.38
|
M
| |
$0.04
|
per share
|
|
EV:
|
$8.36
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($19.2)
|
M
| |
|
|
|
EBIT
|
($19.2)
|
M
| |
|
|
| EPS |
($0.30)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| Revenues | 0.0 | 0.0 | 28.6 | 10.2 | 10.5 | 8.9 | 7.2 | 6.0 |
| Revenue growth | | -100.0% | 180.3% | -2.9% | 18.3% | 23.4% | 20.0% | 0.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 28.6 | 10.2 | 10.5 | 8.9 | 7.2 | 6.0 |
| Gross margin | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 22.3 | 25.2 | 56.9 | 33.8 | 18.7 | 16.2 | 12.6 | 11.0 |
| General and administrative | 8.7 | 9.5 | 13.5 | 13.0 | 10.7 | 10.5 | 7.2 | 4.9 |
| EBIT | -31.0 | -34.7 | -41.9 | -36.6 | -18.9 | -17.8 | -12.6 | -10.0 |
| EBIT margin | | | -146.7% | -359.0% | -180.5% | -200.9% | -175.7% | -166.6% |
| Pre-tax income | -30.8 | -34.7 | -41.9 | -38.0 | -18.4 | -17.1 | -15.1 | -8.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | | | | | |
| Net income | -30.8 | -34.7 | -41.9 | -38.0 | -18.4 | -17.1 | -15.1 | -8.1 |
| Net margin | | | -146.8% | -373.0% | -175.7% | -193.1% | -209.7% | -135.2% |
| |
| Diluted EPS | ($0.50) | ($0.83) | ($1.19) | ($1.42) | ($0.96) | ($0.97) | ($1.37) | ($0.96) |
| Shares outstanding (diluted) | 61.4 | 41.7 | 35.2 | 26.8 | 19.3 | 17.7 | 11.0 | 8.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|